FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage SCLC
Tislelizumab Approved as Second-Line Treatment for Advanced, Metastatic Esophageal Cancer
Officials Provide Update on Phase 3 CheckMate-73L Trial in NSCLC